A method for inhibiting or reducing thalamic damage affected by multiple sclerosis in a subject comprising administering laquinimod； Pharmaceutical composition.
This invention provides methods for inhibiting or reducing thalamic damage in a subject comprising administering to the subject an amount of laquinimod, wherein the subject is a human patient afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome who has been determined to have thalamic damage at baseline, a subject afflicted with a disease or disorder other than a form of multiple sclerosis or a clinically isolated syndrome, or a subject not afflicted with a form of multiple sclerosis or a presenting clinically isolated syndrome, and laquinimod and laquinimod pharmaceutical compositions for use thereof. This invention also provides methods for inhibiting or reducing tremor or spasticity in a subject afflicted by tremor or spasticity, comprising administering to the subject an amount of laquinimod, and laquinimod and laquinimod pharmaceutical compositions for use thereof.USO DE LAQUINIMOD PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR DAÑO TALÁMICO O PARA INHIBIR O REDUCIR TEMBLORES O ESPASTICIDAD EN UN SUJETO CON ESCLEROSIS MÚLTIPLE O SÍNDROME CLÍNICAMENTE AISLADO O CON OTRA ENFERMEDAD.
